eptifibatide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
peptides and glycopeptides 1040 188627-80-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • eptifibatide
  • eftifibatide
  • integrelin
  • integrilin
  • intrifiban
Cyclic peptide that acts as a platelet glycoprotein IIB-IIIA antagonist, reversibly inhibiting the binding of FIBRINOGEN; VON WILLEBRAND FACTOR; and other adhesive molecules to the GPIIB-IIIA RECEPTORS of platelets. It is used in the management of UNSTABLE ANGINA and in patients undergoing coronary ANGIOPLASTY and stenting procedures.
  • Molecular weight: 831.97
  • Formula: C35H49N11O9S2
  • CLOGP: -2.86
  • LIPINSKI: 3
  • HAC: 20
  • HDO: 11
  • TPSA: 323.89
  • ALOGS: -3.67
  • ROTB: 10

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 65 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.68 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.17 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 18, 1998 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Retroperitoneal haemorrhage 207.55 57.25 38 1077 2856 53345095
Thrombocytopenia 99.19 57.25 51 1064 138676 53209275
Thrombosis in device 89.38 57.25 19 1096 3046 53344905
Haemorrhage 61.46 57.25 28 1087 57959 53289992
Haematoma 58.01 57.25 23 1092 33821 53314130
Haemorrhage intracranial 57.42 57.25 18 1097 13334 53334617

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 252.66 41.20 150 2336 148149 32362891
Haemorrhage intracranial 126.45 41.20 47 2439 15840 32495200
Post procedural complication 120.18 41.20 42 2444 11865 32499175
Thrombosis in device 102.37 41.20 28 2458 3506 32507534
Coronary artery thrombosis 84.89 41.20 22 2464 2239 32508801
Vascular stent thrombosis 82.29 41.20 22 2464 2525 32508515
Pulmonary alveolar haemorrhage 75.16 41.20 26 2460 7103 32503937
Haemorrhage 65.64 41.20 43 2443 49405 32461635
Blood creatine phosphokinase MB increased 54.16 41.20 15 2471 1962 32509078
Post procedural haemorrhage 53.20 41.20 21 2465 8279 32502761
Myocardial infarction 49.23 41.20 54 2432 125622 32385418
Procedural complication 45.15 41.20 16 2470 4684 32506356
Vascular pseudoaneurysm 43.99 41.20 13 2473 2141 32508899
Arterial thrombosis 43.51 41.20 12 2474 1544 32509496
Post procedural haematoma 43.15 41.20 12 2474 1592 32509448
Pulmonary haemorrhage 43.14 41.20 19 2467 9838 32501202
Heparin-induced thrombocytopenia 42.10 41.20 16 2470 5698 32505342
Acute myocardial infarction 41.36 41.20 34 2452 55115 32455925

Pharmacologic Action:

SourceCodeDescription
ATC B01AC16 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
FDA PE N0000008832 Decreased Platelet Aggregation
FDA EPC N0000175578 Platelet Aggregation Inhibitor
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
CHEBI has role CHEBI:50249 anticoagulante
CHEBI has role CHEBI:50427 platelet aggregation inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute coronary syndrome indication 394659003
Percutaneous coronary intervention indication 415070008
Acute hemorrhage contraindication 8573003
Blood coagulation disorder contraindication 64779008 DOID:1247
Impaired renal function disorder contraindication 197663003
Hemorrhagic cerebral infarction contraindication 230706003
Renal dialysis contraindication 265764009
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure contraindication 387713003
Hypertensive urgency contraindication 443482000
Acute Thromboembolic Stroke contraindication
Puncture of Noncompressible Artery contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.75 acidic
pKa2 12.86 acidic
pKa3 13.39 acidic
pKa4 13.57 acidic
pKa5 13.79 acidic
pKa6 9.79 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-IIb/beta-3 Adhesion INHIBITOR IC50 6.24 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
4021114 VUID
N0000148569 NUI
D06888 KEGG_DRUG
4021114 VANDF
C0253563 UMLSCUI
CHEBI:291902 CHEBI
CHEMBL1174 ChEMBL_ID
D000077542 MESH_DESCRIPTOR_UI
DB00063 DRUGBANK_ID
6585 IUPHAR_LIGAND_ID
7717 INN_ID
NA8320J834 UNII
448812 PUBCHEM_CID
288688 RXNORM
11710 MMSL
213655 MMSL
4670 MMSL
d04316 MMSL
007557 NDDF
116065005 SNOMEDCT_US
386998009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 0338-9558 INJECTION 75 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 0338-9559 INJECTION 200 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 14335-070 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 14335-071 INJECTION 0.75 mg INTRAVENOUS ANDA 25 sections
EPTIFIBATIDE HUMAN PRESCRIPTION DRUG LABEL 1 16729-259 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 27 sections
EPTIFIBATIDE HUMAN PRESCRIPTION DRUG LABEL 1 16729-260 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 27 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 17478-902 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 26 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 17478-903 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 26 sections
eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 25021-408 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 26 sections
eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 25021-409 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 26 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 52958-402 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 26 sections
Eptifibatide Human Prescription Drug Label 1 55150-218 INJECTION 75 mg INTRAVENOUS ANDA 25 sections
Eptifibatide Human Prescription Drug Label 1 55150-219 INJECTION 20 mg INTRAVENOUS ANDA 25 sections
Eptifibatide Human Prescription Drug Label 1 55150-220 INJECTION 200 mg INTRAVENOUS ANDA 25 sections
Eptifibatide Human Prescription Drug Label 1 62147-0600 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 25 sections
Eptifibatide Human Prescription Drug Label 1 62147-0601 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 25 sections
Eptifibatide Human Prescription Drug Label 1 62147-0602 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 67457-629 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 24 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 67457-630 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 24 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 67457-631 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 24 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1002 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70121-1003 INJECTION 0.75 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70436-026 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70436-027 INJECTION 0.75 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70436-162 INJECTION 2 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70436-163 INJECTION 0.75 mg INTRAVENOUS ANDA 25 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 70860-303 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 27 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 72078-025 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 24 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 72078-026 INJECTION, SOLUTION 0.75 mg INTRAVENOUS ANDA 24 sections
Eptifibatide HUMAN PRESCRIPTION DRUG LABEL 1 72078-027 INJECTION, SOLUTION 2 mg INTRAVENOUS ANDA 24 sections